Key US Patent Granted on Antibodies Against GM-CSF to Treat Inflammatory Disorders
IP Position around MorphoSys's MOR103 Program Significantly Strengthened
27-Nov-2008 -
MorphoSys AG and the University of Melbourne announced that the U.S. Patent & Trademark Office (USPTO) has confirmed that it will issue U.S. Patent No. 7,455,836, covering key uses of antibodies against GM-CSF. The patent stems from a provisional patent application filed in the USPTO in 2000 by ...
antibodies
biopharmaceuticals
clinical trials
+4